Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Acute myeloid leukemia patients 50 years of age or older responded to induction therapy
September 20th, 2006
Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation. "Outcome of patients with AML who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse," investigators in the United States reported. "We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML," explained S. Faderl and colleagues, M.D. Anderson Cancer Center. "Clofarabine was given...
Source: Biotech Week (2006-09-20)
|
